CINECA IRIS Institutional Research Information System

AGATE, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.186
EU - Europa 6.065
AS - Asia 4.793
SA - Sud America 656
AF - Africa 345
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 21.059
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.934
DE - Germania 2.178
SG - Singapore 1.572
CN - Cina 1.345
IT - Italia 1.112
SE - Svezia 824
HK - Hong Kong 716
GB - Regno Unito 580
BR - Brasile 523
VN - Vietnam 347
BG - Bulgaria 273
AT - Austria 233
RU - Federazione Russa 206
FR - Francia 193
CA - Canada 187
TR - Turchia 163
CI - Costa d'Avorio 146
FI - Finlandia 143
IN - India 142
JP - Giappone 122
SN - Senegal 104
KR - Corea 82
UA - Ucraina 79
BD - Bangladesh 58
NL - Olanda 46
AR - Argentina 41
IQ - Iraq 39
CH - Svizzera 38
MX - Messico 37
MA - Marocco 34
PL - Polonia 29
PK - Pakistan 26
VE - Venezuela 24
ZA - Sudafrica 24
BE - Belgio 23
SA - Arabia Saudita 20
CO - Colombia 19
ES - Italia 19
IR - Iran 19
PH - Filippine 19
ID - Indonesia 18
UZ - Uzbekistan 16
EC - Ecuador 14
JO - Giordania 13
IE - Irlanda 12
LT - Lituania 12
CZ - Repubblica Ceca 11
AU - Australia 10
IL - Israele 10
MY - Malesia 10
TW - Taiwan 10
AZ - Azerbaigian 9
CL - Cile 9
UY - Uruguay 9
JM - Giamaica 8
TN - Tunisia 8
SK - Slovacchia (Repubblica Slovacca) 7
EE - Estonia 6
EG - Egitto 6
GR - Grecia 6
LB - Libano 6
PE - Perù 6
PY - Paraguay 6
AL - Albania 5
DZ - Algeria 5
HU - Ungheria 5
KZ - Kazakistan 5
NP - Nepal 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
KE - Kenya 4
KG - Kirghizistan 4
NG - Nigeria 4
PT - Portogallo 4
RO - Romania 4
RS - Serbia 4
BY - Bielorussia 3
CR - Costa Rica 3
PS - Palestinian Territory 3
TH - Thailandia 3
AO - Angola 2
BJ - Benin 2
BZ - Belize 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GA - Gabon 2
GT - Guatemala 2
HN - Honduras 2
MC - Monaco 2
PA - Panama 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
BB - Barbados 1
BH - Bahrain 1
DM - Dominica 1
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
Totale 21.043
Salva come PNG Salva come JPEG
Città #
Ashburn 1.101
Singapore 862
Dallas 755
Hong Kong 697
Woodbridge 658
San Jose 595
Chandler 576
Santa Clara 548
Fairfield 490
Ann Arbor 403
Milan 366
Houston 316
Beijing 296
Sofia 271
New York 265
Shanghai 265
Seattle 217
Vienna 211
Wilmington 209
Los Angeles 190
Cambridge 182
Abidjan 146
London 140
Princeton 138
Boardman 135
Ottawa 112
Lauterbourg 111
Munich 106
Lawrence 105
Dakar 104
Tokyo 103
Florence 95
Jacksonville 92
Frankfurt am Main 91
Hefei 90
Serra 87
Ho Chi Minh City 80
Medford 80
Seoul 74
Rome 63
Pisa 61
Hanoi 60
Nanjing 59
Istanbul 58
Izmir 57
Helsinki 55
Council Bluffs 54
Dearborn 52
Bremen 51
Des Moines 51
Boulder 50
Redondo Beach 50
Dong Ket 49
Buffalo 44
São Paulo 41
San Diego 39
Fuzhou 34
Redmond 34
Orem 32
Turku 29
Lancaster 28
Bern 27
Düsseldorf 25
Redwood City 25
Denver 24
Montreal 24
Ogden 24
Amsterdam 23
Brussels 22
Phoenix 22
Brooklyn 21
Rio de Janeiro 21
Atlanta 20
Belo Horizonte 20
Columbus 20
Guangzhou 20
Nanchang 20
Toronto 20
Washington 20
Baghdad 18
Casablanca 18
Chicago 18
Quanzhou 18
San Francisco 18
Warsaw 17
Jiaxing 16
Kunming 16
Nuremberg 16
Stockholm 15
Tashkent 15
Changsha 14
Poplar 14
Zhengzhou 14
Boston 13
Chengdu 13
Chennai 13
Haiphong 13
Jüchen 13
Pune 13
Amman 12
Totale 13.128
Salva come PNG Salva come JPEG
Nome #
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 317
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 289
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 259
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 254
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 253
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 253
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 248
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 244
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 242
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 240
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 239
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 234
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 233
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 233
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 232
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 227
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 226
Targeted Therapy in Thyroid Cancer: State of the Art 224
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 223
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 217
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 215
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 215
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 213
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 211
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 211
RET point mutations in Thyroid Carcinoma 208
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 206
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 204
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 204
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 203
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 201
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 197
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 196
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 196
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 195
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 194
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 192
Il carcinoma tiroideo: nuove prospettive terapeutiche. 191
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 189
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 184
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 183
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 183
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 180
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 179
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 177
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 177
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 177
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 177
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 176
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 176
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 171
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 171
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 170
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 170
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 169
Thyroid consequences of the Chernobyl nuclear accident. 168
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 167
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 167
Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation 166
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 166
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 164
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 163
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 162
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 161
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 161
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 159
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 158
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 158
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 156
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 155
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 155
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 155
Thyroid incidentaloma 154
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 152
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 152
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 150
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 149
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 149
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 149
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 148
null 146
Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone 145
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 145
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 143
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 143
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments 138
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 138
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 136
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 134
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 133
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 133
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 132
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer 131
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 129
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 128
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 127
Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer 125
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 124
Totale 18.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021130 0 0 0 0 0 0 0 0 0 0 0 130
2021/20221.310 34 46 22 101 284 169 37 56 67 69 89 336
2022/20232.381 277 387 201 185 208 244 43 170 474 21 156 15
2023/20241.592 161 174 220 109 213 281 113 52 28 22 70 149
2024/20254.283 46 153 43 267 479 420 301 216 465 536 416 941
2025/20265.227 401 769 578 457 566 409 804 215 328 466 171 63
Totale 21.329